Key takeaways
- • Trial: SCALE Maintenance (NCT01267617) — Phase 3, 422 participants over 56 weeks.
- • Drug studied: Saxenda (Liraglutide) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from randomization (post low-calorie-diet run-in) to week 56
- • Key result: Additional 6.2% weight loss on liraglutide 3.0mg vs 0.2% on placebo after a 5% LCD lead-in
- • Published: International Journal of Obesity, 2013.
Study design
SCALE Maintenance was a phase 3 randomized controlled trial enrolling 422 participants over 56 weeks. The trial studied Saxenda (Liraglutide) for obesity / overweight and was published in International Journal of Obesity in 2013.
Primary endpoint
Percent change in body weight from randomization (post low-calorie-diet run-in) to week 56
Key results
| Measure | Value |
|---|---|
| Headline result | Additional 6.2% weight loss on liraglutide 3.0mg vs 0.2% on placebo after a 5% LCD lead-in |
| Mean weight loss (highest dose arm) | 6.2% |
| Participants | 422 |
| Duration | 56 weeks |
| Phase | Phase 3 |
Citation
SCALE Maintenance. Published in International Journal of Obesity, 2013.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Saxenda drug page — pricing, FDA status, side effects, alternatives
- All liraglutide trials
- GLP-1 clinical trials database
Other Saxenda trials
- SCALE Obesity and Prediabetes — Mean weight loss 8
Important: This trial was conducted on the FDA-approved branded product Saxenda. Compounded versions of Liraglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.